Gurunanda Anticavity

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the prevention of dental cavities. It is intended for use in individuals at risk of developing dental caries.

Dosage and Administration

Adults and children aged 6 years and older are instructed to use the rinse once daily, following the brushing of teeth with toothpaste. The recommended method involves vigorously swishing 10 mL (2 teaspoonfuls) of the rinse between the teeth for a duration of 1 minute, after which the solution should be expectorated. It is imperative that the rinse is not swallowed. Additionally, patients should refrain from eating or drinking for 30 minutes post-rinsing to ensure optimal efficacy.

For children under 12 years of age, it is essential to instruct them in proper brushing and rinsing techniques to minimize the risk of swallowing the rinse. Supervision is recommended until the child demonstrates the ability to use the product independently.

For children under 6 years of age, consultation with a dentist or physician is advised prior to use.

Contraindications

Use is contraindicated if more than the recommended amount for rinsing is accidentally swallowed. In such cases, immediate medical assistance should be sought or contact with a Poison Control Center (1-800-222-1222) is advised.

Warnings and Precautions

Healthcare professionals should be aware of the following critical warnings and precautions associated with the use of this product.

In the event that an amount exceeding that intended for rinsing is accidentally ingested, it is imperative to seek immediate medical assistance or contact a Poison Control Center at 1-800-222-1222. Prompt action is essential to ensure patient safety and mitigate potential adverse effects.

Healthcare providers are encouraged to educate patients on the proper use of the product to prevent accidental ingestion and to ensure that they are aware of the appropriate steps to take in case of an emergency.

Side Effects

Patients may experience a range of adverse reactions associated with the use of this medication. While specific side effects or warnings were not detailed in the summary product labeling (SPL), it is important for healthcare providers to monitor patients for any unexpected reactions during treatment.

In clinical trials and postmarketing experiences, participants should be informed of the potential for adverse reactions, even if they are not explicitly listed. Continuous evaluation of patient responses is essential to ensure safety and efficacy.

Healthcare professionals are encouraged to report any adverse reactions observed in patients to contribute to the ongoing assessment of the medication's safety profile.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Gurunanda Anticavity (sodium fluoride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be instructed to keep the product out of reach of children. In the event that more than the recommended amount for rinsing is accidentally swallowed, immediate medical assistance should be sought or the Poison Control Center contacted at 1-800-222-1222.

The product is indicated for use in adults and children aged 6 years and older. It is recommended to use the rinse once daily after brushing teeth with toothpaste. Patients should vigorously swish 10 mL (2 teaspoonfuls) of the rinse between their teeth for 1 minute and then spit it out. It is important that the rinse is not swallowed, and patients should refrain from eating or drinking for 30 minutes following rinsing.

For children under 12 years of age, caregivers should instruct them in proper brushing and rinsing techniques to minimize the risk of swallowing the rinse. Supervision is advised until children are capable of using the product independently. For children under 6 years of age, consultation with a dentist or doctor is recommended prior to use.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

There is no specific information regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. The potential risks and benefits should be carefully evaluated, and alternative treatments may be considered in consultation with the patient. Women of childbearing potential should be advised to discuss their pregnancy status and any plans for pregnancy with their healthcare provider prior to initiating treatment.

Lactation

Nursing mothers should consult a healthcare professional before using this product. There is a potential for excretion in breast milk; therefore, caution is advised when administering to nursing mothers. The effects on the nursing infant are not well studied; thus, the risks versus benefits should be considered.

Renal Impairment

There is no specific information regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Patients should be evaluated for potential complications, and appropriate interventions should be implemented based on clinical judgment.

For further guidance, healthcare professionals may refer to established protocols for managing drug overdosage or consult a poison control center.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the understanding of the compound's potential effects in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. It is important to inform patients that if more than the recommended amount used for rinsing is accidentally swallowed, they should seek medical assistance immediately or contact a Poison Control Center at 1-800-222-1222. This guidance is crucial for ensuring patient safety and prompt action in case of an emergency.

Storage and Handling

The product is supplied in packaging that includes a printed seal. It is imperative that the product not be used if the printed seal is broken or missing, as this may compromise the integrity of the product.

For optimal storage, the recommended temperature range is between 59°F and 77°F (15°C to 25°C). Proper adherence to these storage conditions is essential to maintain the product's efficacy and safety.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Gurunanda Anticavity, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)